Risk/Benefit Of Asthma Drugs To Be Debated At Future Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA awaits data from controlled trials of seven long-acting beta agonists before bringing them back for panel review later this year.
You may also be interested in...
AstraZeneca Submits Symbicort For Asthmatics As Young As Six
Lead investigator touts inhaler's safety profile.
AstraZeneca Submits Symbicort For Asthmatics As Young As Six
Lead investigator touts inhaler's safety profile.
AstraZeneca Wants COPD Label For Symbicort
Newly reported trials prove safety and efficacy, company says.